Feeley Kevin

GeneDx CFO Kevin Feeley sold 8,818 shares at blended $63.17 on 2026-03-26, reducing holdings 20.3%; stock now -64.4% from 52-week high.

Kevin Feeley, GeneDx CFO, executed five separate sales totaling 8,818 shares for $557,051.44 at prices ranging from $61.29 to $65.21 on 2026-03-26, liquidating 20.3% of his pre-transaction holdings. The timing is notable: his prior five trades at WGS (all sales on 2025-12-16) displayed a 5-of-5 well-timed pattern at the 90-day mark, with post-sale declines ranging from -45.2% to -49.0%, and the stock has since fallen -64.4% from its 52-week high of $167.52 to a current price of $59.61. Despite strong revenue growth of +40.0% year-over-year, the company remains unprofitable (net income of $-7.6M in the latest quarter, full-year loss in the most recent fiscal year), creating a context of fundamental weakness that aligns with the insider's repeated divestiture pattern at this ticker. The current price of $59.61 sits below the blended transaction price of $63.17, marking a near-immediate mark-to-market loss on this filing's sales.

CFO Kevin Feeley sold 3,855 shares at GeneDx for $554,616.10; reduces stake 30.6% to 8,731 shares

Kevin Feeley, GeneDx CFO, executed 11 separate sales totaling 3,855 shares (3.9K shares) for $554,616.10 ($554.6K) on 2025-12-16, reducing his holdings by 30.6% from 12,586 shares to 8,731 shares. The blended average transaction price of $143.87 sits above the current price of $136.32, indicating the stock has declined -18.6% from its 52-week high of $167.52, though it remains up 7.4% over the prior 30 days. His same-ticker history shows 5 prior sells on 2025-09-30, each with positive 30-day returns (ranging from +15.7% to +25.0%), though none yet have measurable 90-day outcomes; his cross-ticker track record shows a 84.62% well-timed rate at the 90-day mark. GeneDx remains unprofitable with -$7.6M net income on $116.7M quarterly revenue despite strong 50.8% annual revenue growth, and its P/E ratio of 1947.43 reflects an unprofitable pricing environment. The substantial reduction in CFO holdings warrants investor attention given the company's unprofitable status and elevated valuation relative to earnings.

CFO Feeley sells 6,609 shares (66.1% of holdings) at $105.24–$113.68 on 2025-09-30 for $716,260.64

Kevin Feeley, Chief Financial Officer, executed 7 separate sales totaling 6,609 shares (6.6K shares) for $716,260.64 on 2025-09-30, reducing his position from 10,001 shares to 3,392 shares post-transaction. The blended average price of $108.38 sits near the current price of $113.44, but the stock has fallen 14.4% from its 52-week high and declined 12.4% over the past 30 days. Across his prior trades at WGS, 4 of 5 sell transactions were well-timed at the 90-day mark, and the prior April 2025 sales resulted in subsequent 30-day declines of -29.3% to -39.2%. The company traded on a P/E of 2268.80 following a loss-making fiscal year despite 50.8% annual revenue growth, creating an elevated valuation backdrop at a moment when the stock has already retraced significantly from recent peaks.

GeneDx CFO Kevin Feeley sells 15,516 shares for $1.4M; reduces holdings by 90.0% to 1.7K shares

Kevin Feeley, Chief Financial Officer, executed 9 separate sales totaling 15,516 shares for $1,430,334.40 on 2025-04-09, at prices ranging from $83.67 to $97.26 with a blended average of $92.18. This represents a -90.0% reduction in his holdings, leaving him with only 1,726 shares (1.7K shares) post-transaction. His prior trades at WGS show a 3 of 3 well-timed pattern at the 90-day mark, with -33.4%, -35.6%, and -35.0% declines following his January 7 sells, suggesting a consistent ability to sell ahead of downturns at this ticker. The current stock price of $92.62 is -17.9% from the 52-week high, and the company is unprofitable with net income of $-8.3M on quarterly revenue of $76.9M, despite 50.8% annual revenue growth. The near-complete liquidation by the CFO, combined with his historical timing pattern at this ticker, warrants investor attention.

CFO Kevin Feeley sold 8.7K shares (35.3% of holdings) at blended $95.61 on 2025-03-26; stock now $92.20.

Kevin Feeley, CFO of GeneDx Holdings, executed 2 separate sales totaling 8,746 shares for $836,210.93, reducing his holdings by 35.3% to 16.0K shares post-transaction. The sales occurred at $95.66 and $94.40, above the current price of $92.20, yet his prior 4 same-ticker sales on 2025-01-07 each showed 30-day declines ranging from -33.4% to -35.6%, suggesting a pattern of selling into strength. Notably, of his prior 5 measurable same-ticker trades, only 1 had a well-timed outcome at the 90-day mark, indicating inconsistent timing precision. The company trades at a P/E of 64.93 with a most recent quarter net income of $-8.3M, and while revenue growth stands at +50.8% annually, the unprofitable operating profile amid elevated valuation suggests heightened execution risk that may be influencing the CFO's portfolio decision.

GeneDx CFO Kevin Feeley sells 35,506 shares (93.5% of holdings) in 4 transactions for $3.3M on 2025-01-07

Kevin Feeley executed four separate sales totaling 35,506 shares for $3,331,024.29 at prices ranging from $93.32 to $96.52, reducing his stake from 37,978 shares to 2,472 shares—a near-complete liquidation representing a 93.5% reduction. The blended average price of $93.82 sits near the 52-week high of $97.04, and the current price of $89.38 reflects a subsequent 4.7% decline from the transaction prices. GeneDx operates within a challenged context: the company reported negative net income of $-8,312,000.00 in its latest quarter, declined 13.7% year-over-year in annual revenue, and remains unprofitable on a full-year basis. Feeley's prior trades at this ticker show mixed short-term outcomes (30-day returns ranging from -0.0% to +11.2% across 5 prior sales since November 2024), and his cross-ticker track record of 9 prior sells averaged +5.2% 30-day returns, providing no predictive signal for this transaction's near-term price trajectory. The near-complete reduction in holdings by the company's CFO warrants scrutiny regarding capital allocation strategy and conviction levels at the current valuation.

CFO Kevin Feeley sold 22,000 shares (48.9% of holdings) at $69.58–$77.40 for $1,645,810.28 on Nov 21–22, 2024.

Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), executed 9 separate sales totaling 22,000 shares for $1,645,810.28 over two trading days, reducing his stake from 44,951 shares to 22,951 shares—a reduction of nearly half his holdings. The sales occurred across a price range of $69.58 to $77.40, with a blended average price of $74.81, while the stock currently trades at $80.46 (4.2% below its 52-week high of $84.02). This large liquidation is notable given the company's negative financial trajectory: GeneDx posted a net loss of $8,312,000.00 against quarterly revenue of $76,874,000.00, and annual revenue has declined 13.7% year-over-year, reflecting an unprofitable operating environment. The magnitude of this sale—nearly half the CFO's holdings—represents a material reduction of executive equity stakes at a company facing profitability headwinds.